Document Detail

Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
MedLine Citation:
PMID:  22458577     Owner:  NLM     Status:  In-Data-Review    
Atrial fibrillation (AF) is a major cause of ischemic stroke, especially in the elderly. There are currently enough data to support the notion that anticoagulation with warfarin or dabigatran is far superior to aspirin in the prevention of stroke or systemic embolism in AF. Aspirin is the preferred modality in patients who are either not candidates for anticoagulation, such as patients with increased risk for bleeding, low-risk patients based on the CHADS2 score or patients who have difficulty in maintaining a therapeutic international normalized ratio. There is no dispute on the recommendations regarding stroke prevention in high-risk patients (CHADS2 risk score of 2 and beyond) with AF. However, there is some controversy regarding the appropriate strategy (anticoagulation vs aspirin) for stroke prevention in low-risk patients (CHA2DS2-VASc score of 0-1). Novel oral anticoagulant drugs (direct thrombin inhibitors and Factor Xa inhibitors) might further diminish the role of aspirin for stroke prevention in AF due to their superior efficacy, lack of need for monitoring of therapeutic effects and lower bleeding risk when compared with warfarin, especially in patients with stable vascular disease.
Mohit K Turagam; Poonam Velagapudi; Miguel A Leal; Abraham G Kocheril
Related Documents :
25142827 - Characterization of the relationship between intracranial pressure and electroencephalo...
6951477 - Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis.
3873207 - Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after dis...
15853917 - Antibodies against extractable nuclear antigen in non-hodgkin lymphoma patients.
23050867 - Ovarian failure in hax-1 deficient patients: is there a gender-specific difference in p...
25465417 - New ischemic stroke and outcomes with vorapaxar versus placebo: results from the tra 2...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  10     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  433-9     Citation Subset:  IM    
Department of Medicine, University of Wisconsin School of Medicine and Public Health, 3116 MFCB, 1685 Highland Avenue, Madison, WI 53705, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-elut...
Next Document:  New technologies aimed at percutaneous intervention in the small coronary artery.